[ad_1]
New Brunswick, New Jersey, December 5, 2021 /PRNewswire/–Johnson & Johnson (New York Stock Exchange stock code:Johnson) (The company) today announced the preliminary results of an independent study, which included part of the participants in the COV2008 study sponsored by Janssen. Dan Baruch, MD, Ph.D., etc. A study by the Beth Israel Deaconess Medical Center (BIDMC) showed that a booster injection of Johnson & Johnson’s COVID-19 vaccine (Ad26.COV2.S) six months after the two-dose BNT162b2 main program can increase two kinds of antibodies and T cell responses. These results demonstrate the potential benefits of heterogeneous enhancement (mix and match).An article describing these results has been published in Medicine Magazine.
“There is early evidence that, compared with the homology enhancement method, the mixed-match enhancement method may provide individuals with a different immune response against COVID-19,” Dan Baruch, MD, Ph.D., Director of BIDMC Virology and Vaccine Research Center. “In this preliminary study, when an individual was given a booster dose of Ad26.COV2.S six months after the main regimen of the BNT162b2 vaccine, the antibody response in the 4th week after the booster increased considerably, and compared with BNT162b2 , The CD8+ T cell response of Ad26.COV2.S.”
“These results provide valuable scientific insights for our vaccine’s use as a mix-and-match booster, and help inform boost strategies aimed at containing the pandemic,” Matama gate, MD, Ph.D., Global Head of R&D at Johnson & Johnson Janssen. “These data add more and more evidence that the booster dose of the Johnson & Johnson COVID-19 vaccine mixed and matched successfully increased the humoral response and cellular response against the original SARS-CoV-2 strain, as well as Beta and Delta variants. .”
The preliminary results of the British COV-BOOST clinical study confirm these Phase 2 data LancetThis indicates that after the first two doses of BNT162b2 (n=106) or ChAdOx1 nCov-19 (n=108), the booster dose of Johnson & Johnson’s COVID-19 vaccine increased antibody and T cell responses.
Cell (T cell) response
In this preliminary study, boosting with Johnson & Johnson’s COVID-19 vaccine after the BNT162b2 main vaccine regimen seems to lead to an increase in CD8+ T cell responses more than boosting with BNT162b2. These T cell response data show that there is a difference between the immune response after homologous enhancement using BNT162b2 and the mixed and matched immune response after using the Johnson & Johnson COVID-19 vaccine after using the BNT162b2 main program.
Johnson & Johnson’s COVID-19 vaccine utilizes Janssen’s AdVac® Technology and cell-mediated immunity, including CD4+ and CD8+ responses. T cells can target and destroy cells infected by the virus that causes COVID-19. Specifically, CD8+ T cells can directly destroy infected cells and get the help of CD4+ T cells.
Humoral (antibody) reaction
Johnson & Johnson’s COVID-19 vaccine and BNT162b2 as boosters produced similar levels of neutralizing and binding antibodies against the original SARS-CoV-2 strain and the Delta and Beta variants 4 weeks after the boost. However, after mixing and matching the booster dose of Johnson & Johnson’s COVID-19 vaccine, the antibody continued to increase for at least 4 weeks, while in individuals who received the BNT162b2 vaccine homologous booster, the antibody dropped four times from the second week to one week and then increased.
Neutralizing antibodies can bind to the virus in a way that blocks infection and confines the virus to the upper respiratory tract. The binding antibody can bind to the spike protein of the virus and inactivate the virus through non-neutralizing antiviral function.
Study plan
In this study, a biobank at Beth Israel Deaconess Medical Center (BIDMC) obtained samples from individuals who received the BNT162b2 vaccine. Participants either continue to follow up in the biobank and use 30 ug BNT162b2 (n = 24) for reinforcement, or participate in the COV2008 study (NCT04999111) and use 5, 2.5 or 1×1010 Vice President of Johnson & Johnson COVID-19 Vaccine (n=41). The COV2008 study is an ongoing, double-blind phase 2 clinical trial (VAC31518COV2008) sponsored by Johnson & Johnson, which aims to evaluate the promotion of its COVID-19 vaccine on adults 18 years of age and older.
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the Johnson & Johnson COVID-19 vaccine as a booster for all eligible individuals 18 years of age and older who receive an approved COVID-19 vaccine.
Johnson & Johnson continues to submit relevant data to other regulatory agencies, the World Health Organization (WHO) and the National Immunization Technical Advisory Agency…
The full story can be found on Benzinga.com
[ad_2]
Source link
